3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Glioblastoma
3
Glioma
2
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lipodystrophy, Congenital Generalized
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hodgkin Disease
1
Astrocytoma
1
Advanced Cancer
1
Interventions
Cyclophosphamide
48
fludarabine phosphate
45
fludarabine
38
Whole-Body Irradiation
38
Mycophenolic Acid
37
Imatinib Mesylate
36
nilotinib
34
Tacrolimus
30
Busulfan
23
Cyclosporine
18
Melphalan
17
Granulocyte Colony-Stimulating Factor
17
Dasatinib
17
thymoglobulin
16
Methotrexate
16
Thiotepa
15
Peripheral Blood Stem Cell Transplantation
15
Antilymphocyte Serum
15
bosutinib
13
Filgrastim
13
Stem Cell Transplantation
11
sargramostim
8
ponatinib
8
Cytarabine
8
Cyclosporins
8
Cord Blood Stem Cell Transplantation
8
Clofarabine
8
Sirolimus
7
Rituximab
7
plerixafor
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
Tetanus Toxoid
×
Clear all
NCT01611298
2020-04-21
TAR
Baylor College of Medicine
Phase NA
Completed
7 enrolled
8 charts